Latest Advances in Obesity Treatment by Regulating Adipocyte Thermogenesis
Nie T., Chen J., Wang Z., Mao L.
Narrative Review, published in PPAR Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- PPAR Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42339133
- PMCID
- PMC13284497
- DOI
- 10.1155/ppar/1742256
Abstract (original English)
Obesity is driven by chronic energy imbalance and is associated with multiple metabolic diseases. As adipocyte thermogenesis contributes to energy expenditure, it is being actively investigated as a possible target for obesity treatment. This review summarizes recent progress in the molecular regulation of adipocyte thermogenesis, focusing mainly on preclinical mechanistic evidence from cellular and animal studies, while discussing clinical and human data only where available. We review emerging regulators within the cAMP pathway, the PRDM16-PPAR γ axis, and mitochondrial quality control and metabolism, together with other pathways that modulate brown and beige adipocyte function. We also discuss their metabolic effects in experimental obesity settings. Nevertheless, the therapeutic relevance of these findings remains uncertain because much of the evidence is still preclinical, and because translation is complicated by species differences, adipose depot heterogeneity, and the limited number of validated human studies. This review therefore offers an updated synthesis of recent mechanistic advances while emphasizing the key challenges that must be addressed before these insights can be reliably translated into obesity therapies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.